MDMA-assisted therapies are generating growing interest due to their potential to address deep trauma and emotional blockages that are difficult to treat with conventional methods. MDMA, administered in a structured clinical setting, can promote a state of emotional openness and reduce fear responses, facilitating the safe processing of difficult experiences.
This type of intervention is part of clinical programmes and regulated studies, where each session is accompanied by prior preparation, therapeutic guidance, and a subsequent integration process. In specialised and authorised settings, the aim is to provide a safe space to explore emotions, work through trauma, and promote significant changes in mental health, always within the current legal framework.
On 20 March, Málaga will host a series of talks exploring the relationship between psychedelics and mental health. Specialists and professionals will discuss current research, their therapeutic potential and the challenges of applying them in clinical practice.
MDMA, first synthesized in 1912, has moved from recreational use to becoming the focus of growing scientific interest for its therapeutic potential. Discover how it works, its role in PTSD treatment, and what other clinical applications are currently being explored.
For centuries we believed personality was fixed, carved in stone by adulthood. A new systematic review — analyzing 48 studies on psilocybin, LSD, and ayahuasca — suggests otherwise: our deepest traits, from Openness to Neuroticism, may be far more malleable than we thought. We explore five key findings from psychedelic science and the philosophical questions they raise about the “self.”
Fear is a fundamental emotion that protects us, but when it becomes chronic it can lead to disorders such as phobias and post-traumatic stress disorder (PTSD). Conventional treatments often show limited efficacy, prompting new approaches like MDMA-assisted psychotherapy. Research promoted by Multidisciplinary Association for Psychedelic Studies (MAPS) and led by figures such as Rick Doblin suggests that MDMA can reduce fear responses, enhance emotional processing, and strengthen the therapeutic alliance. These effects may allow patients to revisit traumatic memories with less avoidance, fostering recovery and improved quality of life.
Phil Wolfson, creator of Ketamine-Assisted Psychotherapy (KAP) and director of the Ketamine Research Foundation, shares his vision on the future of psychedelic psychotherapy in this in-depth interview. Drawing from decades of clinical practice and research, he reflects on ketamine’s unique therapeutic flexibility, the risks of over-regulation and corporatization, and the importance of preserving the psychedelic experience within clinical care. Wolfson also discusses training, ethics, accessibility, and why ketamine currently plays a central role in advancing mental health treatment worldwide.